HK1008485A1 - Vascular endothelial growth factor-b. - Google Patents

Vascular endothelial growth factor-b.

Info

Publication number
HK1008485A1
HK1008485A1 HK98108852A HK98108852A HK1008485A1 HK 1008485 A1 HK1008485 A1 HK 1008485A1 HK 98108852 A HK98108852 A HK 98108852A HK 98108852 A HK98108852 A HK 98108852A HK 1008485 A1 HK1008485 A1 HK 1008485A1
Authority
HK
Hong Kong
Prior art keywords
vascular endothelial
polypeptides
growth factor
endothelial growth
vegf
Prior art date
Application number
HK98108852A
Other languages
English (en)
Inventor
Ulf Eriksson
Birgitta Kling Olofsson
Kari Alitalo
Katri Pajusola
Original Assignee
Ludwig Inst Cancer Res
Univ Helsinki Licensing
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1008485(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/469,427 external-priority patent/US5607918A/en
Application filed by Ludwig Inst Cancer Res, Univ Helsinki Licensing filed Critical Ludwig Inst Cancer Res
Publication of HK1008485A1 publication Critical patent/HK1008485A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK98108852A 1995-03-01 1998-07-03 Vascular endothelial growth factor-b. HK1008485A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39765195A 1995-03-01 1995-03-01
US08/469,427 US5607918A (en) 1995-03-01 1995-06-06 Vascular endothelial growth factor-B and DNA coding therefor
US08/569,063 US5928939A (en) 1995-03-01 1995-12-06 Vascular endothelial growth factor-b and dna coding therefor
PCT/US1996/002957 WO1996026736A1 (en) 1995-03-01 1996-03-01 Vascular endothelial growth factor-b

Publications (1)

Publication Number Publication Date
HK1008485A1 true HK1008485A1 (en) 1999-07-30

Family

ID=27410265

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98108852A HK1008485A1 (en) 1995-03-01 1998-07-03 Vascular endothelial growth factor-b.

Country Status (15)

Country Link
US (5) US5928939A (no)
EP (1) EP0814827B1 (no)
JP (2) JP3275024B2 (no)
CN (1) CN1146440C (no)
AT (1) ATE245437T1 (no)
AU (1) AU741856B2 (no)
CA (1) CA2211687C (no)
DE (1) DE69629181T2 (no)
DK (1) DK0814827T3 (no)
ES (1) ES2202432T3 (no)
HK (1) HK1008485A1 (no)
NO (1) NO973933L (no)
NZ (1) NZ305091A (no)
PT (1) PT814827E (no)
WO (1) WO1996026736A1 (no)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2249762T3 (es) 1994-03-08 2006-04-01 Human Genome Sciences, Inc. Factor de crecimiento del endotelio vascular 2.
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7109308B1 (en) * 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6040157A (en) * 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US7160991B1 (en) 1995-03-02 2007-01-09 Ludwig Institute For Cancer Research Vascular endothelial growth factor polypeptides
CA2214439C (en) * 1995-03-02 2002-12-17 Amrad Operations Pty. Ltd. A novel growth factor and a genetic sequence encoding same
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
EP0873348A4 (en) * 1995-06-06 2000-11-08 Human Genome Sciences Inc GROWTH FACTOR 3 OF THE HUMAN VASCULAR ENDOTHELIUM
US7727761B2 (en) * 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
WO1997009427A1 (en) 1995-09-08 1997-03-13 Genentech, Inc. Vegf-related protein
WO1997012972A2 (en) 1995-09-29 1997-04-10 Universita'degli Studi Di Siena Regulated genes and uses thereof
WO1997017442A1 (en) 1995-11-08 1997-05-15 Immunex Corporation Flk-1 binding protein
US6994989B1 (en) 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
CA2263890C (en) 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
WO1998024811A2 (en) * 1996-12-06 1998-06-11 Zymogenetics, Inc. Vascular endothelial growth factor
AU742779B2 (en) * 1996-12-20 2002-01-10 Licentia Oy VEGF-B/receptor complex and uses thereof
AU6691098A (en) 1997-03-07 1998-09-22 Wistar Institute Of Anatomy & Biology, The Method and compositions for healing tissue defects and inducing hypervascularityin mammalian tissue
CN1260835A (zh) * 1997-04-25 2000-07-19 科莱特诺医疗公司 截短的vegf相关蛋白质
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
AU767662B2 (en) 1998-02-06 2003-11-20 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: VEGF
US20030118567A1 (en) * 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)
EP1129110B1 (en) 1998-11-10 2009-12-09 Ludwig Institute For Cancer Research Platelet-derived growth factor d, dna coding therefor, and uses thereof
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
AU3693000A (en) * 1999-01-29 2000-08-18 Licentia Ltd Platelet-derived growth factor/vascular endothelial growth factor-like growth factor h, and uses thereof
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
AU3614700A (en) * 1999-03-03 2000-09-21 Ludwig Institute For Cancer Research Heart abnormalities in vascular endothelial growth factor b (vegf-b) deficient animals and methods relating to these heart abnormalities
WO2000064261A1 (en) * 1999-04-26 2000-11-02 Ludwig Institute For Cancer Research Role of vascular endothelial growth factor-b (vegf-b) in developing bones and uses thereof
WO2000075329A1 (en) * 1999-06-07 2000-12-14 Edwards Lifesciences Corporation Targeted angiogenesis
US8188043B2 (en) * 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
DE60040293D1 (de) * 1999-07-28 2008-10-30 Univ R Verwendung von nikotin in der angiogenese und der vaskulogenese
DE60136334D1 (en) * 2000-02-02 2008-12-11 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
AUPQ568100A0 (en) * 2000-02-16 2000-03-09 Amrad Operations Pty. Limited A method for producing recombinant molecules
AU2001239884B2 (en) * 2000-02-25 2006-08-10 Vegenics Limited Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
AUPQ592100A0 (en) * 2000-02-29 2000-03-23 Council Of The Queensland Institute Of Medical Research, The A method of treatment and prophylaxis
US20030104977A1 (en) * 2000-03-31 2003-06-05 Ugo Ripamonti Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
CA2405701A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001261705A1 (en) * 2000-05-17 2001-11-26 Ludwig Institute For Cancer Research Methods for detecting for the presence of tumor cells and for screening for anti-tumor agents
EP1303594A4 (en) * 2000-07-26 2004-07-14 Ludwig Inst Cancer Res GLYCOSYLATED VEGF-B AND METHOD FOR INCREASING THE QUANTITY OF SOLUBLE VEGF-B
CN1211126C (zh) * 2000-08-04 2005-07-20 人体基因组科学有限公司 血管内皮生长因子2
US20020151489A1 (en) * 2000-10-02 2002-10-17 St. Elizabeth's Medical Center Of Boston, Inc. Use of lymphangiogenic agents to treat lymphatic disorders
AU2002224471A1 (en) * 2000-11-01 2002-05-15 Aventis Pharma S.A. In vivo stimulation of angiogenic activity
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7026462B2 (en) * 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US20070111944A1 (en) * 2001-02-16 2007-05-17 Scrofani Sergio D B Purification of vascular endothelial growth factor-B
US20070050857A1 (en) * 2001-02-28 2007-03-01 Hayward Nick K Method of treatment and prophylaxis
AU2002303261A1 (en) * 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
CA2444624A1 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
WO2002083850A2 (en) * 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
DK1407276T3 (da) * 2001-04-24 2009-12-21 Vlaams Interuniv Inst Biotech Anvendelse af hypoxia-inducerbar faktor 2-alfa til helbredelse af neonatalt respiratory distress syndrom
WO2003000009A2 (en) * 2001-06-20 2003-01-03 Ludwig Institute For Cancer Research Stimulation of vascularization with vegf-b
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
AU2002319402B2 (en) * 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
JP2005500045A (ja) * 2001-07-12 2005-01-06 ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ リンパ管内皮細胞材料および方法
US7217570B2 (en) 2001-08-23 2007-05-15 The Wistar Institute Of Anatomy And Biology Organotypic intestinal culture and methods of use thereof
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
US20030221931A1 (en) 2002-02-28 2003-12-04 Steve Marsh Sliding device
US20040005671A1 (en) * 2002-05-17 2004-01-08 Amrad Operations Pty Ltd. Immunointeractive molecules
EP1912069A3 (en) 2002-06-05 2008-07-09 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
US20030235864A1 (en) * 2002-06-05 2003-12-25 Sopherion Therapeutics, Inc. Method to screen ligands using eukaryotic cell display
US20030232439A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2366718A3 (en) * 2002-06-28 2012-05-02 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
CA2493572A1 (en) 2002-07-23 2004-01-29 Ludwig Institute For Cancer Research Methods and compositions for activating or inhibiting vegf-d and vegf-c
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
US20040258670A1 (en) * 2002-12-05 2004-12-23 Case Western Reserve University Cell-based therapies for ischemia
JP2006523090A (ja) * 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
AU2004209668A1 (en) * 2003-02-04 2004-08-19 Flanders Interuniversity Institute For Biotechnology VEGF-B and PDGF modulation of stem cells
US7759472B2 (en) 2003-08-27 2010-07-20 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
WO2005067889A1 (en) 2003-12-30 2005-07-28 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
WO2005084329A2 (en) * 2004-03-02 2005-09-15 Ludwig Institute For Cancer Research Method for inhibiting tumor formation and growth
US20060024302A1 (en) * 2004-03-05 2006-02-02 Ludwig Institute For Cancer Research Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
AU2005232665B2 (en) * 2004-04-08 2010-05-13 Sangamo Therapeutics, Inc. Methods and compositions for treating neuropathic and neurodegenerative conditions
DK1781321T3 (da) * 2004-08-02 2014-04-14 Zenyth Operations Pty Ltd Fremgangsmåde til behandling af cancer, der omfatter en vegf-b-antagonist
US7595149B1 (en) 2004-11-08 2009-09-29 University Of Kentucky Research Foundation Methods for cancer detection
JP4988606B2 (ja) * 2005-02-28 2012-08-01 サンガモ バイオサイエンシズ インコーポレイテッド 抗血管新生方法及び組成物
CN101277704A (zh) * 2005-04-12 2008-10-01 因特拉迪格姆公司 用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
ATE502956T1 (de) 2005-08-15 2011-04-15 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
KR20080077238A (ko) * 2005-12-01 2008-08-21 도만티스 리미티드 인터루킨 1 수용체 타입 1에 결합하는 비경쟁적 도메인항체 포맷
AU2007254243B2 (en) 2006-05-17 2013-06-13 Ludwig Institute For Cancer Research Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases
WO2008085229A2 (en) * 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
BRPI0812398A2 (pt) * 2007-06-06 2019-09-24 Domantis Ltd domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
US7819579B2 (en) * 2007-11-26 2010-10-26 Schmulenson Harold K Radiation sensing device and holder
WO2009075565A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Methods for controlling vasculogenesis
CA2710680C (en) 2007-12-26 2018-10-16 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
US20110150900A1 (en) * 2008-04-09 2011-06-23 Ludwig Institute For Cancer Research Regulation of fatty acid transporters
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
KR101335203B1 (ko) * 2010-03-26 2013-11-29 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
RU2477529C2 (ru) * 2011-04-28 2013-03-10 Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" Способ коррекции эндотелиальной дисфункции раствором гомеопатических разведений антител к эндотелиальной синтазе оксида азота человека
BR112016000546A2 (pt) 2013-07-12 2017-11-21 Ophthotech Corp métodos para tratar ou prevenir condições oftalmológicas
CN105979965B (zh) * 2013-12-18 2021-07-09 杰特有限公司 治疗伤口的方法
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
US10745454B2 (en) * 2018-01-31 2020-08-18 Seyed Mohsen Asghari Method of synthesizing antagonist peptides for cell growth
CN109337931A (zh) * 2018-11-02 2019-02-15 东北师范大学 Vegfb基因的应用及vegfb肿瘤诱导和肿瘤抑制动物模型的构建方法
CN110777146A (zh) * 2019-11-28 2020-02-11 南通大学 一种pdgfb启动子活性报告质粒的构建方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5726152A (en) * 1990-09-21 1998-03-10 Merck & Co., Inc. Vascular endothelial cell growth factor II
ES2249762T3 (es) * 1994-03-08 2006-04-01 Human Genome Sciences, Inc. Factor de crecimiento del endotelio vascular 2.
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
CA2214439C (en) * 1995-03-02 2002-12-17 Amrad Operations Pty. Ltd. A novel growth factor and a genetic sequence encoding same
EP0873348A4 (en) * 1995-06-06 2000-11-08 Human Genome Sciences Inc GROWTH FACTOR 3 OF THE HUMAN VASCULAR ENDOTHELIUM

Also Published As

Publication number Publication date
JP2000228982A (ja) 2000-08-22
DE69629181D1 (de) 2003-08-28
AU5302196A (en) 1996-09-18
WO1996026736A1 (en) 1996-09-06
EP0814827A1 (en) 1998-01-07
CA2211687C (en) 2011-05-24
PT814827E (pt) 2003-11-28
CN1176603A (zh) 1998-03-18
CN1146440C (zh) 2004-04-21
CA2211687A1 (en) 1996-09-06
DE69629181T2 (de) 2004-05-13
JP3275024B2 (ja) 2002-04-15
JP3297687B2 (ja) 2002-07-02
JPH10510718A (ja) 1998-10-20
US5928939A (en) 1999-07-27
DK0814827T3 (da) 2003-11-10
NO973933L (no) 1997-09-01
US6331301B1 (en) 2001-12-18
EP0814827A4 (en) 1999-11-10
NZ305091A (en) 1998-11-25
US5840693A (en) 1998-11-24
NO973933D0 (no) 1997-08-27
ES2202432T3 (es) 2004-04-01
EP0814827B1 (en) 2003-07-23
US20050064493A1 (en) 2005-03-24
AU741856B2 (en) 2001-12-13
ATE245437T1 (de) 2003-08-15
US20030170253A1 (en) 2003-09-11
US7341996B2 (en) 2008-03-11

Similar Documents

Publication Publication Date Title
HK1008485A1 (en) Vascular endothelial growth factor-b.
HK1025789A1 (en) Recombinant vascular endothelial cell growth factor d (vegf-d)
WO1994011503A3 (en) Chimeric factor viii
WO1993016099A3 (en) Dna sequences encoding novel growth/differentiation factors
DE69435096D1 (de) Zusammensetzung zur in vivo erzeugung von therapeutischen produkten
EP1005540A4 (en) IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHODS
EP2014678A3 (en) KDR peptides and vaccines comprising the same
IL193886A (en) Antibodies that bind to ldcam sequences
ATE229977T1 (de) Peptide mit antiproliferativen eigenschaften
NZ510121A (en) Use of VEGF-C or VEGF-D gene or protein to prevent restenosis of blood vessels
IL106894A0 (en) Dorsal tissue affecting factor and compositions
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
WO1998012220A3 (en) Novel tumor proteins
WO2001010382A3 (en) Compositions and methods related to claudin-7

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120301